Next-Generation Biologics: Improving on Monoclonal Antibodies

Table of Contents

• Executive Summary
  • Strategic Considerations
  • Stakeholder Implications
• Introduction
• The Structure of an Antibody
• Improving on Monoclonal Antibodies
  • Development
  • Manufacturing
  • Cost
  • Competition and Royalty Stacking
  • Delivery
  • Immunogenicity
• Industry Interest and Clinical Development
• Remaining Challenges for MAb Alternatives
• Appendix A. Types of Biologic Alternatives to Therapeutic Monoclonal Antibodies

Tables

• 1. MAb Alternatives in Clinical Development
• 2. Licensing and Comarketing Deals Involving MAb Alternatives, 2000-2007
• 3. Acquisitions Involving MAb Alternatives, 1999-2007

Figures

• 1. Market Growth of Biotherapeutics and Small-Molecule Drugs, 2002-2006
• 2. Share of Monoclonal Antibodies in the Biologics Market, 2002-2008
• 3. Structure of an Antibody
• 4. MAb Alternatives by Development Stage, 2007
• 5. Deals Involving MAb Alternatives, 2000-2007
• 6. MAb Alternatives in Development, by Therapeutic Area, 2007